Why I see 50% upside in this pharmaceutical firm in 2017

Bilaal Mohamed explains why this pharamceutical firm could have massive growth potential over the coming year.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

When it comes to stock picking, UK-focused investors seeking income from within the pharmaceuticals sector will no doubt be fully aware of the generous dividends available from FTSE 100 giants GlaxoSmithKline and AstraZeneca. Both these multinational drugmakers are currently handing out substantial payouts to shareholders, with chunky dividend yields around the 5% mark, and there’s certainly nothing wrong with that.

Industry leader

However, growth-focused investors will tell you that over the years the pharmaceuticals sector has also been home to some spectacular growth plays, with previously unheard of companies like Hikma Pharmaceuticals and Shire plc finding their way into the blue-chip index on the back of rapid sales and earnings growth. Consequently, the share price of both these firms has tripled within the last five years.

But don’t worry, while both Hikma and Shire continue to offer attractions for growth seekers, there are other smaller and often overlooked firms that I believe could have similar growth potential in the coming years. One such firm is FTSE 250-listed Vectura Group (LSE: VEC). The Chippenham-based business is an industry leader specialsing in inhaled therapies for the treatment of respiratory diseases, with last reported revenues of £72m and a market value just shy of £1bn.

Step-change

In June last year Vectura completed its merger with rival SkyePharma, and consequently decided to move its year-end-date from 31 March to 31 December, leaving a shortened post-merger year of just nine months. Full-year results for the year ending 31 December aren’t due until March, but in a pre-close trading update last week the company said it has made significant business development progress following on from the step-change in financial performance announced in its interim results in November.

During the first six months of the shortened year Vectura boasted a massive 183% rise in revenue to £73.9m, compared to the same period a year earlier, helped in no small part by the £441m merger with SkyePharma. The group continues to see sustained momentum in recurring revenues from recently launched inhaled products, and now owns or is partered with seven assets that are currently in Phase III development or under regulatory review.

Strong start to 2017

Vectura starts 2017 in a very strong position, with significant progress made with the pipeline and sustained growth in recurring revenues driven by seven recently launched inhaled products. Sales have risen sharply in recent years, and the City expects revenues to double by 2019. The group is forecast to report pre-tax profits of £15m for 2016, rising to £47m for 2017, and £93m for 2018.

The valuation isn’t too demanding either, with the P/E ratio dropping to just 11 by 2019 after anticipated earnings growth of 69% and 54% for the next two years. I believe the current P/E rating significantly undervalues the company given its longer-term growth appeal. If all goes well, investors willing to take on a higher level of risk could be sitting on terrific gains by the end of the year.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Bilaal Mohamed has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing For Beginners

It’s down 50%. Would it be madness for me to buy this value stock?

Jon Smith notes down a household value stock in the FTSE 250 that he thinks can rally in the long…

Read more »

Midnight is celebrated along the River Thames in London with a spectacular and colourful firework display.
Investing Articles

Up 70% and 80%! I’m thrilled I bought these two red-hot UK stocks exactly 1 year ago

Harvey Jones bought two UK stocks at the end of November last year, and both have smashed the market in…

Read more »

Investing Articles

These FTSE 100 shares could soar over the next year

FTSE 100 shares show strong potential as rate cuts loom. History shows stocks could gain more than 70% in the…

Read more »

Young Black woman using a debit card at an ATM to withdraw money
Investing Articles

“If I’d put £5,000 into Santander shares just 2 years ago, here’s what I’d have now”

Our writer considers whether he thinks Santander shares still look good value after a strong period for the global Spanish…

Read more »

Illustration of flames over a black background
Investing Articles

Could this FTSE 250 stock be the next Rolls-Royce?

With an ongoing probe into the motor finance industry, the share price of this member of the FTSE 250 has…

Read more »

Investing Articles

My 3 favourite FTSE dividend stocks give me a mind-blowing 9.82% yield!

Harvey Jones is surprised to learn that he owns the three highest-yielding dividend stocks on the FTSE 100. So is…

Read more »

Investing Articles

Following strong 2024 results, this 6.1%-yielding FTSE 100 gem looks a bargain to me

With good 2024 results delivered, and a buyback and dividend increase announced, this high-yielding FTSE 100 heavyweight looks very cheap…

Read more »

Investing Articles

I’m not surprised the IAG share price is surging, it’s the top-rated UK stock

The IAG share price is up 57% since the start of the year, but remains undervalued. This bull run could…

Read more »